Team

 

Tiffany Ferry – President

Founder and President of Lymphatic Malformation Institute since December 2010.

 

 

 

Dr. Michael Dellinger – Director of Research

Dr. Michael Dellinger -Assistant Professor in the Departments of Surgery and Molecular Biology at UT Southwestern Medical Center

Dr. Michael Dellinger is an Assistant Professor in the Departments of Surgery and Molecular Biology at UT Southwestern Medical Center. He is also a member of the Hamon Center for Regenerative Science and Medicine and is the Director of Research for the Lymphatic Malformation Institute. Dr. Dellinger completed his Ph.D. work at the University of Arizona and his postdoctoral studies at UT Southwestern Medical Center. His lab is focused on identifying biomarkers and treatments for Gorham-Stout disease, generalized lymphatic anomaly and kaposiform lymphangiomatosis.

 

Dr. Michael Kelly – Chief Medical Officer

jpeg image of MK.jpg

Dr. Michael Kelly joined the LGDA and LMI in June of 2020 in a newly created position, Chief Medical Officer, where he will provide strategic oversight for foundation initiatives related to patient care and clinical and translational research.Dr. Kelly attended the University of Cincinnati in 1980-1985, staying on to finish his MD, PhD in 1993. Dr. Kelly then completed his Pediatric residency and Hematology/Oncology fellowship at Washington University in St. Louis in 1998.  He was the Pediatric Cancer Program Director at the Medical College of Wisconsin, Children’s Hospital of Wisconsin and most recently the Chief Research Officer at Akron Children’s Hospital. Dr. Kelly’s research has focused on developing new, “first in children” therapies for pediatric cancer and vascular anomalies. He has over twenty years’ experience in the care of children and adults with vascular anomalies.  In his role as CMO, Dr. Kelly will help organize and strengthen national and international collaborations that promote our understanding of complex lymphatic anomalies (CLAs) with the goal of providing more effective and safer therapies for children and adults with CLAs.